Lexeo Therapeutics (LXEO) Cash & Equivalents (2022 - 2026)

Lexeo Therapeutics has reported Cash & Equivalents for 5 years, with the latest figure at $71.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 148.22% year-over-year to $71.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.8 million (up 148.22% YoY) and the FY2025 annual result came in at $63.0 million, up 79.93% from the prior year.
• Cash & Equivalents grew to $71.8 million in Q1 2026 per LXEO's latest filing, from $63.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $195.1 million in Q1 2024 and troughed at $28.9 million in Q1 2025.
• A 5-year average of $87.0 million and a median of $71.8 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 342.89% in 2024, then plunged 85.18% in 2025.
• Over 5 years, Cash & Equivalents stood at $77.3 million in 2022, then surged by 57.06% to $121.5 million in 2023, then slumped by 71.17% to $35.0 million in 2024, then soared by 79.93% to $63.0 million in 2025, then grew by 13.92% to $71.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $71.8 million, $63.0 million, and $41.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.